AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8000941 — intervention group
Group type: EXPERIMENTAL
Intervention: Head covering with two terry cloth towels until UBT reached 37 degrees C
Number of subjects: 40
Study 8000941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no head covering)
Number of subjects: 40
Study 8000941 — intervention group
Group type: EXPERIMENTAL
Intervention: Head covering
Number of subjects: 40
Study 8000941 — intervention group
Group type: EXPERIMENTAL
Intervention: Shiverers (both groups)
Number of subjects: 40
Study 1771604 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms twice daily)
Number of subjects: 40
Study 1771604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7025675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic calf compression
Number of subjects: 119
Study 7025675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 119
Study 30771791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial agents, N-acetylcysteine
Number of subjects: 0
Study 30771791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28126360 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2g/d omega-3 PUFA (n=38)
Number of subjects: 79
Study 28126360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 79
Study 26396135 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of ALC hydrochloride 590 mg
Number of subjects: 0
Study 26396135 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of ALC hydrochloride 590 mg
Number of subjects: 0
Study 23637314 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelter residence
Number of subjects: 113
Study 23637314 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and standardized measures of IPV, trauma, and depression
Number of subjects: 113
Study 23637314 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma symptoms, housing instability, and ethnicity
Number of subjects: 113
Study 21429452 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-18 level
Number of subjects: 75
Study 21429452 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP level
Number of subjects: 75
Study 21429452 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 21429452 — intervention group
Group type: COMPARATOR
Intervention: Disease control (HCV-related chronic liver disease)
Number of subjects: 75
Study 19479183 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI patients
Number of subjects: 23
Study 19479183 — intervention group
Group type: COMPARATOR
Intervention: CAD patients
Number of subjects: 23
Study 17719296 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin 400 U/kg
Number of subjects: 96
Study 17719296 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin 100 U/kg
Number of subjects: 96
Study 17719296 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin 200 U/kg
Number of subjects: 96
Study 17719296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 15118425 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 20
Study 11444885 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous carbon-dioxide insufflations (10 treatments) and standard physical treatment
Number of subjects: 0
Study 11444885 — intervention group
Group type: COMPARATOR
Intervention: Standard physical treatment only
Number of subjects: 0
Study 9745404 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH + GHRP-2
Number of subjects: 20
Study 9745404 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 alone
Number of subjects: 20
Study 9745404 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-2
Number of subjects: 20
Study 9745404 — intervention group
Group type: COMPARATOR
Intervention: Placebo or TRH
Number of subjects: 20
Study 8111939 — intervention group
Group type: EXPERIMENTAL
Intervention: Decubitus position for 30 min after epidural blood patch
Number of subjects: 30
Study 8111939 — intervention group
Group type: EXPERIMENTAL
Intervention: Decubitus position for 60 min after epidural blood patch
Number of subjects: 30
Study 8111939 — intervention group
Group type: EXPERIMENTAL
Intervention: Decubitus position for 120 min after epidural blood patch
Number of subjects: 30
Study 8111939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 3207854 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen SR 800 mg
Number of subjects: 12
Study 3207854 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg followed by ibuprofen SR 800 mg
Number of subjects: 12
Study 3207854 — intervention group
Group type: COMPARATOR
Intervention: conventional ibuprofen tablets (2 x 400 mg)
Number of subjects: 12
Study 29208322 — intervention group
Group type: COMPARATOR
Intervention: NPPV alone (NPPV-a)
Number of subjects: 64
Study 29208322 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV with nasal cannula at 15L/min (NPPV-nc)
Number of subjects: 64
Study 28803012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus rhamnosus SD11
Number of subjects: 43
Study 28803012 — intervention group
Group type: COMPARATOR
Intervention: Fermented milk containing Lactobacillus bulgaricus
Number of subjects: 43
Study 26654223 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) training for practice nurses
Number of subjects: 11
Study 26654223 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex physical activity consultations
Number of subjects: 11
Study 26654223 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the trial
Number of subjects: 11
Study 23764108 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention focusing on existential issues and nurses' perceived confidence in communication.
Number of subjects: 102
Study 23764108 — intervention group
Group type: COMPARATOR
Intervention: Non-training group (control).
Number of subjects: 102
Study 21982663 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program
Number of subjects: 2604
Study 21982663 — intervention group
Group type: COMPARATOR
Intervention: Non-QI group (control)
Number of subjects: 2604
Study 18304310 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and follow-up supervision (experimental group)
Number of subjects: 79
Study 18304310 — intervention group
Group type: COMPARATOR
Intervention: No training and supervision (control group)
Number of subjects: 79
Study 17154777 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed forgetting instruction with varying forget signal delays
Number of subjects: 0
Study 17154777 — intervention group
Group type: COMPARATOR
Intervention: Default instruction to remember
Number of subjects: 0
Study 12708395 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmycin in combination with Cefasolin
Number of subjects: 50
Study 12708395 — intervention group
Group type: COMPARATOR
Intervention: Gentamycin in combination with Cefasolin
Number of subjects: 50
Study 11885180 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile implants at placement
Number of subjects: 800
Study 11885180 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mobile implants at placement
Number of subjects: 800
Study 11885180 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants (mobile at placement)
Number of subjects: 800
Study 11885180 — intervention group
Group type: COMPARATOR
Intervention: Non-HA-coated implants (mobile at placement)
Number of subjects: 800
Study 11885180 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants (non-mobile at placement)
Number of subjects: 800
Study 11885180 — intervention group
Group type: COMPARATOR
Intervention: Non-HA-coated implants (non-mobile at placement)
Number of subjects: 800
Study 8967866 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1421911 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of 4 mg/kg of trimethoprim coupled with 17.5 mg/kg of sulphadiazine for 3 days (group 1)
Number of subjects: 40
Study 1421911 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of 4 mg/kg of trimethoprim coupled with 17.5 mg/kg of sulphadiazine for 10 days (group 2)
Number of subjects: 40
Study 3880875 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol and adenine therapy
Number of subjects: 14
Study 3880875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30914464 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP)
Number of subjects: 452
Study 30914464 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
Number of subjects: 452
Study 28865065 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm fluoride rinse
Number of subjects: 12
Study 28865065 — intervention group
Group type: COMPARATOR
Intervention: 1500 ppm fluoride rinse
Number of subjects: 12
Study 27427807 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 131
Study 27427807 — intervention group
Group type: COMPARATOR
Intervention: Literature control
Number of subjects: 131
Study 24924647 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflecting on romantic partner
Number of subjects: 0
Study 24924647 — intervention group
Group type: COMPARATOR
Intervention: Reflecting on opposite-sex friend
Number of subjects: 0
Study 24924647 — intervention group
Group type: COMPARATOR
Intervention: Reflecting on morning routine
Number of subjects: 0
Study 22608783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in AViTA (77 patients)
Number of subjects: 264
Study 22608783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in AVOREN (59 patients)
Number of subjects: 264
Study 22608783 — intervention group
Group type: COMPARATOR
Intervention: Placebo in AViTA
Number of subjects: 264
Study 22608783 — intervention group
Group type: COMPARATOR
Intervention: Placebo in AVOREN
Number of subjects: 264
Study 19732250 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting groups (Incredible Years programme and SPOKES programme)
Number of subjects: 112
Study 19732250 — intervention group
Group type: COMPARATOR
Intervention: Control (information helpline)
Number of subjects: 112
Study 16998861 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Severity Index and Symptom Impact Index (SSI/SII)
Number of subjects: 291
Study 16998861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bristol Female Lower Urinary Tract Symptom Questionnaire (BFLUTS)
Number of subjects: 291
Study 16998861 — intervention group
Group type: EXPERIMENTAL
Intervention: Kings Health Questionnaire (KHQ)
Number of subjects: 291
Study 15766298 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine (ERC-CBZ)
Number of subjects: 239
Study 15766298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 12392342 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS (Manchester Active Position Seat)
Number of subjects: 4
Study 10638770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide pulse therapy (750 mg/m2) for 12 months; concurrent prednisone (10 mg/day)
Number of subjects: 16
Study 10638770 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide (2-2.5 mg/kg/day) for 12 months; concurrent prednisone (10 mg/day)
Number of subjects: 16
Study 7781174 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal gel every 12 hours, initial dose of 2 mg followed by two additional doses at 12 hour intervals if not in active labor.
Number of subjects: 70
Study 7781174 — intervention group
Group type: COMPARATOR
Intervention: PGE2 vaginal gel every 6 hours, initial dose of 1 mg followed by 2 mg at 6 hour intervals for a maximum of two additional doses if not in active labor.
Number of subjects: 70
Study 7781174 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal gel every 12 hours
Number of subjects: 70
Study 7781174 — intervention group
Group type: COMPARATOR
Intervention: PGE2 vaginal gel every 6 hours
Number of subjects: 70
Study 7781174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 1969770 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg.kg‐1 after d-tubocurarine 0.05 mg.kg‐1, intubation after 60 seconds
Number of subjects: 0
Study 1969770 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg.kg‐1 after d-tubocurarine 0.05 mg.kg‐1, intubation after 90 seconds
Number of subjects: 0
Study 1969770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.01 mg.kg‐1 followed by 0.1 mg.kg‐1, intubation after 60 seconds
Number of subjects: 0
Study 1969770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.01 mg.kg‐1 followed by 0.1 mg.kg‐1, intubation after 90 seconds
Number of subjects: 0
Study 1969770 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (Group IV)
Number of subjects: 0
Study 1969770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (Group III)
Number of subjects: 0
Study 6986040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 30
Study 6986040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30705244 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered cognitive-behavioural approaches (CBAs)
Number of subjects: 375
Study 30705244 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised exercise programme interventions
Number of subjects: 375
Study 30705244 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 375
Study 28945667 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Group (n = 29)
Number of subjects: 85
Study 28945667 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Group (n = 29)
Number of subjects: 85
Study 28945667 — intervention group
Group type: COMPARATOR
Intervention: Delayed Group (n = 73)
Number of subjects: 85
Study 26414902 — intervention group
Group type: EXPERIMENTAL
Intervention: early adenotonsillectomy (eAT)
Number of subjects: 322
Study 26414902 — intervention group
Group type: COMPARATOR
Intervention: watchful waiting/supportive care (WWSC)
Number of subjects: 322
Study 26414902 — intervention group
Group type: EXPERIMENTAL
Intervention: eAT
Number of subjects: 322
Study 26414902 — intervention group
Group type: COMPARATOR
Intervention: WWSC
Number of subjects: 322
Study 23286246 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day palmvitee supplementation
Number of subjects: 0
Study 23286246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22120944 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxytocin gel for seven days
Number of subjects: 20
Study 22120944 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel for seven days
Number of subjects: 20
Study 22120944 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxytocin gel
Number of subjects: 20
Study 22120944 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study 19480654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 6800 International Units daily for one year
Number of subjects: 200
Study 19480654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 19480654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Number of subjects: 200
Study 17318994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Cardiac Outpatient Telemetry (MCOT)
Number of subjects: 266
Study 17318994 — intervention group
Group type: COMPARATOR
Intervention: Standard Loop Event Monitor (LOOP)
Number of subjects: 266
Study 15496221 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine 50 mg alone
Number of subjects: 12
Study 15496221 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 50 mg with donepezil 5 mg daily for 2 weeks
Number of subjects: 12
Study 12536625 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (1 mg.kg‐1, oral) pretreatment 48 hours before operation
Number of subjects: 20
Study 12536625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special treatment)
Number of subjects: 20
Study 12536625 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril group
Number of subjects: 20
Study 12536625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined magnetic field (CMF) bone growth stimulation
Number of subjects: 31
Study 9879046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CMF stimulation)
Number of subjects: 31
Study 8024908 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 0.75 mg kg‐1 i.v.
Number of subjects: 42
Study 8024908 — intervention group
Group type: COMPARATOR
Intervention: morphine 0.1 mg kg‐1 i.v. and metoclopramide 0.15 mg kg‐1
Number of subjects: 42
Study 2811970 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of lithium (serum concentration 0.8 to 1.0 mmol per liter)
Number of subjects: 94
Study 2811970 — intervention group
Group type: COMPARATOR
Intervention: Low dose of lithium (serum concentration 0.4 to 0.6 mmol per liter)
Number of subjects: 94
Study 825780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (surgery followed by chemotherapy, second-look laparotomy, and subsequent whole abdominal radiation)
Number of subjects: 97
Study 825780 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (external radiation and single alkylating agent chemotherapy)
Number of subjects: 97
Study 825780 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple chemotherapy (cyclophosphamide, dactinomycin, and 5-fluorouracil)
Number of subjects: 97
Study 825780 — intervention group
Group type: COMPARATOR
Intervention: Single agent therapy with melphalan
Number of subjects: 97
Study 31981556 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help Plus
Number of subjects: 694
Study 31981556 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 694
Study 29882635 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Extinction Training (SET)
Number of subjects: 62
Study 29882635 — intervention group
Group type: COMPARATOR
Intervention: OT-TENS
Number of subjects: 62
Study 29882635 — intervention group
Group type: COMPARATOR
Intervention: AE-BRT
Number of subjects: 62
Study 28422632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense training 3×/wk for 6 wk (18 hr)
Number of subjects: 17
Study 28422632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 17
Study 26710810 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA
Number of subjects: 53
Study 26710810 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 53
Study 23718705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 grams/day for 5 days) with chloroquine (3 days of oral weight-based dosing)
Number of subjects: 12
Study 23718705 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine and primaquine (standard doses)
Number of subjects: 12
Study 21743431 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain®
Number of subjects: 26
Study 21743431 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 26
Study 21743431 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 26
Study 19706349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl iontophoretic transdermal system (ITS)
Number of subjects: 1305
Study 19706349 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 1305
Study 16700803 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg SC
Number of subjects: 686
Study 16700803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 686
Study 14499423 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (20 mg)
Number of subjects: 12
Study 14499423 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-morphine (20 mg THC + 30 mg morphine)
Number of subjects: 12
Study 14499423 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (30 mg)
Number of subjects: 12
Study 14499423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14499423 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-morphine
Number of subjects: 12
Study 10682226 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 22
Study 10682226 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg (active control)
Number of subjects: 22
Study 10682226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8979174 — intervention group
Group type: EXPERIMENTAL
Intervention: Baylor square
Number of subjects: 49
Study 8979174 — intervention group
Group type: EXPERIMENTAL
Intervention: Double square
Number of subjects: 49
Study 8979174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahrmann technique
Number of subjects: 49
Study 8979174 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular position
Number of subjects: 49
Study 8979174 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 49
Study 8104273 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 10-20 mg daily for 3 weeks
Number of subjects: 16
Study 8104273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2868412 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (30 mg/kg)
Number of subjects: 262
Study 2868412 — intervention group
Group type: COMPARATOR
Intervention: Standard brain‐oriented intensive care
Number of subjects: 262
Study 28815639 — intervention group
Group type: COMPARATOR
Intervention: VVZ‐149 (0.25-8 mg/kg)
Number of subjects: 66
Study 28815639 — intervention group
Group type: COMPARATOR
Intervention: VVZ‐149 (4-7 mg/kg, twice daily for 3 days)
Number of subjects: 66
Study 28815639 — intervention group
Group type: EXPERIMENTAL
Intervention: VVZ‐149 (0.5-8 mg/kg)
Number of subjects: 66
Study 28815639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66